Celularity Inc has closed the merger with GX Acquisition Corp (NASDAQ: GXGX), giving Celularity $138 million to push the NK cell and T cell therapies into early-stage trials. <br /> The combined company will operate under the name Celularity Inc (NASDAQ: CELU), and its common stock will commence trading on the NASDAQ from Monday (19 July) under the ticker symbol CELU. <br /> The company expanded its ongoing Phase 1 trial of CYNK-001 in patients with acute myeloid leukemia (AML)to include patients with relapsed/refractory AML (r/r AML) in addition to its ongoing trial in measurable residual disease (MRD). <br /> To date, no dose-limiting toxicity was observed with outpatient administration of three doses. <br /> The FDA granted Orphan Drug Designation to CYNK-001 for the treatment of patients with malignant gliomas. <br /> CYNK-001 is currently in a Phase 1 trial for glioblastoma multiforme. <br /> For Phase 1/2 COVID-19 trial assessing CYNK-001, no evidence of dose-limiting toxicities or evidence of no worsening inflammatory biomarkers was observed, and enrollment is ongoing.